XOMA Royalty (XOMA) EBITDA Margin (2011 - 2026)
XOMA Royalty's (XOMA) quarterly EBITDA Margin came in at 3.87% in Q1 2026, down 15217.0% year-on-year from N/an in Q1 2025, and up 34.03% quarter-over-quarter from 5.87% in Q4 2025.
XOMA Royalty (XOMA) EBITDA Margin (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed EBITDA Margin across 16 years of filings, most recently posting 3.87% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 3.87%, down 15217.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.47% (up 1064.0% YoY), and the FY2025 annual result was 12.83%, up 15313.0% from the prior year.
- EBITDA Margin came in at 3.87% for Q1 2026 at XOMA Royalty, up from 5.87% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 318.11% in Q2 2024 to a low of 62548.0% in Q3 2024.
- The 5-year median for EBITDA Margin is 576.85% (2024), against an average of 4193.24%.
- Across the five-year window, EBITDA Margin slumped 6188427 bps in 2024 and surged 6195778 bps in 2025, its largest moves.
- XOMA Royalty's EBITDA Margin stood at 402.15% in 2022, then plunged by 173 bps to 1097.05% in 2023, then plunged by 32 bps to 1450.2% in 2024, then soared by 100 bps to 5.87% in 2025, then surged by 34 bps to 3.87% in 2026.
- The last three EBITDA Margin figures came in at 3.87% (Q1 2026), 5.87% (Q4 2025), and 590.22% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -3.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87% |
| Dec 31, 2025 | -5.87% |
| Sep 30, 2025 | -590.22% |
| Jun 30, 2025 | 91.66% |
| Mar 31, 2025 | 148.30% |
| Dec 31, 2024 | -1,450.20% |
| Sep 30, 2024 | -62,548.00% |
| Jun 30, 2024 | 318.11% |
| Mar 31, 2024 | -576.85% |
| Dec 31, 2023 | -1,097.05% |
| Sep 30, 2023 | -663.73% |
| Jun 30, 2023 | -784.88% |
| Mar 31, 2023 | -2,245.54% |
| Dec 31, 2022 | -402.15% |
| Sep 30, 2022 | -926.39% |
| Jun 30, 2022 | -475.08% |
| Mar 31, 2022 | -73.38% |
| Dec 31, 2021 | 14,922.00% |
| Sep 30, 2021 | -471.91% |
| Jun 30, 2021 | -248.28% |